721 related articles for article (PubMed ID: 23850330)
1. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
[TBL] [Abstract][Full Text] [Related]
2. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
[TBL] [Abstract][Full Text] [Related]
4. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.
Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS
Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129
[TBL] [Abstract][Full Text] [Related]
5. Applied multimodal diagnostics in a case of presenile dementia.
Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A
BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761
[TBL] [Abstract][Full Text] [Related]
6. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
Sakurai H; Hanyu H
Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
[TBL] [Abstract][Full Text] [Related]
7. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.
Khan TK; Alkon DL
J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622
[TBL] [Abstract][Full Text] [Related]
10. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
[TBL] [Abstract][Full Text] [Related]
11. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
Blennow K; Zetterberg H
Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
13. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Alzheimer's disease.
Pauwels EK; Volterrani D; Mariani G
Drug News Perspect; 2009 Apr; 22(3):151-60. PubMed ID: 19440558
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174
[TBL] [Abstract][Full Text] [Related]
16. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
Shoji M
Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia.
Rostgaard N; Waldemar G; Nielsen JE; Simonsen AH
Dement Geriatr Cogn Disord; 2015; 40(1-2):54-62. PubMed ID: 25998699
[TBL] [Abstract][Full Text] [Related]
18. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic changes in Alzheimer's disease: A leading role behind the courtain? Commentary on "CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease" by Lista et al.
Diomedi M; Stefani A
Alzheimers Dement; 2015 Sep; 11(9):1123-4. PubMed ID: 25487913
[No Abstract] [Full Text] [Related]
20. Biomarkers for preclinical Alzheimer's disease.
Tan CC; Yu JT; Tan L
J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
